Sam Brusco, Associate Editor01.08.24
Butterfly Network has obtained U.S. Food and Drug Administration (FDA) clearance for its next-gen, handheld point-of-care ultrasound (POCUS), Butterfly iQ3.
Butterfly iQ3 has a new ergonomic design and delivers double the data processing speed for optimized image resolution, sensitivity, and penetration, according to the company. It also has faster 3D capabilities to power new automated image capture modes iQ Slice and iQ Fan.
“Butterfly iQ3 is the turning point for digital ultrasound. Butterfly started a revolution in ultrasound when we commercialized the world’s first fully digital handheld ultrasound in 2018, and subsequently, iQ+ in 2020,” said Joseph DeVivo, Butterfly Network’s president, CEO, and chairman. “Over 145,000 customers have since realized the value of our chip-based ultrasound. With iQ3, the revolution takes full charge. Physicians across disciplines now rank our overall image quality at least equal to traditional piezoelectric-based handhelds, and our new digital capabilities are designed to make ultrasound more accessible and approachable than ever before.”
DeVivo continued, “I look forward to revealing more about iQ3’s advanced imaging capabilities this week at the 42nd Annual J.P. Morgan Healthcare Conference. Stay tuned for more details about the product and its commercial launch in the United States this quarter.”
In December, Butterfly Network began a commercial deal with Mendaera for interventional robotics.
Butterfly iQ3 has a new ergonomic design and delivers double the data processing speed for optimized image resolution, sensitivity, and penetration, according to the company. It also has faster 3D capabilities to power new automated image capture modes iQ Slice and iQ Fan.
“Butterfly iQ3 is the turning point for digital ultrasound. Butterfly started a revolution in ultrasound when we commercialized the world’s first fully digital handheld ultrasound in 2018, and subsequently, iQ+ in 2020,” said Joseph DeVivo, Butterfly Network’s president, CEO, and chairman. “Over 145,000 customers have since realized the value of our chip-based ultrasound. With iQ3, the revolution takes full charge. Physicians across disciplines now rank our overall image quality at least equal to traditional piezoelectric-based handhelds, and our new digital capabilities are designed to make ultrasound more accessible and approachable than ever before.”
DeVivo continued, “I look forward to revealing more about iQ3’s advanced imaging capabilities this week at the 42nd Annual J.P. Morgan Healthcare Conference. Stay tuned for more details about the product and its commercial launch in the United States this quarter.”
In December, Butterfly Network began a commercial deal with Mendaera for interventional robotics.